Biological Dynamics, Inc., a leader in exosome technology, today announced that Hoag has joined the growing list of customers adopting Biological Dynamics’ ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform. ExoVerita Pro supports exosome-based research efforts, helping to accelerate early disease detection, determine therapeutic response, and more.
Read MoreBiological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, today announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown.
Read MoreBiological Dynamics, Inc., the leader in exosome-isolation technology, today announced the first opportunity for external users to access the company’s ExoVerita Pro, a cost-efficient, automated exosomal enrichment platform that delivers samples with best-in-class yields, purity, and reproducibility.
Read MoreBiological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in Nature’s Communications Medicine titled “Development of a Blood-Based EV Classifier for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma.” The research demonstrates the effectiveness of exosome-isolation technology in detecting Stage I and II pancreatic ductal adenocarcinoma (PDAC), using an independent validation cohort.
Read MoreBiological Dynamics, Inc., a leader in exosome enrichment technology for early disease detection, will present a “lightning talk” as part of the “Understanding Pre-cancers to Enable Early Detection” track at the Early Detection of Cancer Conference, Oct. 10-12, 2023, in London. The session will demonstrate the ability of the ExoVita Pancreas assay to risk-stratify Intraductal Papillary Mucinous Neoplasms (IPMNs), the most common type of pancreatic cyst, in order to help inform treatment decisions for patients at risk of pancreatic cancer.
Read MoreBiological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, and the Pancreatic Cancer Early Detection (PRECEDE) Consortium, an international, multi-institutional group of experts focused on increasing survival rates for pancreatic cancer patients, have signed a multi-year agreement to partner on patient surveillance for early-stage pancreatic cancer using Biological Dynamics’ ExoVita Pancreas Assay, powered by the Verita platform.
Read MoreBiological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in the journal Electrophoresis titled, “Enhancement of Dielectrophoresis-Based Particle Collection from High Conducting Fluids Due to Partial Electrode Insulation.” The collaborative research with Oregon Health & Science University (OHSU) sheds light on the phenomenon occurring on Biological Dynamics’ ExoVerita platform that allows for the capture of biomarkers carried by nanoscale particles.
Read MoreBiological Dynamics, a leader in exosome-isolation technology for early disease detection, will present a poster featuring its ExoLuminate study design, currently enrolling, at The American Society of Clinical Oncology (ASCO), June 2-6, 2023 in Chicago, IL.
Read MoreBiological Dynamics, a life sciences company focused on developing and commercializing exosome isolation technology for earlier disease detection, today announced the publication of a case report, “Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy,” in Frontiers in Oncology, highlighting the successful detection of early-stage pancreatic ductal adenocarcinoma (PDAC) lesions using its exosome liquid biopsy assay, ExoVitaTM Pancreas.
Read MoreBiological Dynamics, a life sciences company focused on developing and commercializing exosome isolation technology for earlier disease detection, will present data showing how the company’s ExoVeritaTM platform can be utilized for early detection of lung and pancreatic cancers at the American Association of Cancer Research (AACR) annual meeting in Orlando, Fl., April 14-19. A case study of early pancreatic cancer management will also be discussed at the meeting. Biological Dynamics’ will exhibit its technology and early cancer detection assays at booth #1368.
Read MoreBiological Dynamics, Inc., an emerging growth life sciences company commercializing its ExoVerita™ platform for exosome-isolation and ExoVita™ Pancreas assay for the early detection of pancreatic cancer, has appointed Zach Miller as a member of its Board of Directors. Miller will provide strategic guidance and direction for the Company as it enters a period of rapid growth and commercial operations.
Read MoreBiological Dynamics, Inc., a company developing and commercializing its exosome-isolation ExoVerita™ platform for early disease diagnostics and other applications, announced its collaboration with the Brenden-Colson Center for Pancreatic Care at Oregon Health & Science University (OHSU) to study its ExoVita™ Pancreas assay. The Brenden-Colson Center has a robust, integrated clinical-translational interface to drive innovative patient care and nourish scientific collaborations.
Read MoreBiological Dynamics, Inc., a company commercializing its exosome-isolation ExoVerita™ platform for early disease surveillance and other applications, today announced completion of the analytical and clinical validation of its lab developed test (LDT), ExoVita™ Pancreas in the company’s CLIA certified and CAP accredited laboratory.
Read MoreStudy to investigate effectiveness of early-stage pancreatic cancer detection using patented exosome-isolation technology
Read MoreBiological Dynamics, a company developing and commercializing its ExoVeritaTM platform for early disease diagnostics, announced today that Harmeet Dhani, MD, MSc, Medical Director will present at the Precision Medicine World Conference (PMWC) in Santa Clara, Calif.
Dr. Dhani’s PMWC showcase presentation on January 26th is part of the Clinical Utility of Liquid Biopsies track. The track focuses on how liquid biopsy technologies facilitate detection of early-stage cancer, which could help contribute to improving patient outcomes rates and reduce the need for invasive diagnostic procedures.
Biological Dynamics’ ExoVerita platform targets extracellular vesicles in blood, isolating exosomes to detect biomarkers of early-stage cancers. Its first product is an assay for pancreatic ductal adenocarcinoma (PDAC) assay that identifies exosomal PDAC-associated protein biomarkers, detecting Stage 1 and 2 pancreatic cancers with high sensitivity, a key advantage of the technology. Dr. Dhani’s presentation will discuss the implication of exosomes, the ExoVerita technology platform, review a subject case study, and provide an overview of the preliminary data in multi-cancer early detection and the ExoLuminate registry trial (NCT05625529) which enrolled its first subject in December.
“Leveraging the innovations of our ExoVerita platform, we are developing solutions for patients, their families and the medical community. We believe our decade of expertise in isolating exosomes will significantly improve a patient’s diagnostic journey, including with future clinical applications for multiple cancers,” noted Dr. Dhani.
Dr. Dhani is a surgeon scientist with a background in abdominal transplant and hepato-pancreato-biliary (HPB) surgery. He also holds a Master’s in Clinical Research from UCSD and anticipates completing his MBA from Georgetown University in 2025.
About Biological Dynamics
Biological Dynamics, Inc. is committed to improving global health outcomes by detecting diseases at the earliest stages. The company's proprietary ExoVerita™ platform simplifies isolation of extracellular vesicles, enabling multiomic applications. Its PDAC test operates in a College of American Pathologists (CAP) accredited, CLIA-certified clinical laboratory in San Diego. Biological Dynamics recently announced the initiation of the ExoLuminate study, a clinical trial to demonstrate effectiveness of early-stage detection of pancreatic cancer. Learn more at www.ExoLuminate.com.
To learn more about the application of exosome-isolation technology for the detection of Stage 1 and 2 cancers, visit Biological Dynamics in booth D3526.
Disclaimer: Biological Dynamics does not provide any diagnostic results for patients and has no authority, responsibility, or liability with respect to any clinical decisions made by – or in connection with – a provider. Nothing herein and no aspect of any engagement between Biological Dynamics and its collaborating institutions is intended – or shall be deemed – to subordinate, usurp, or otherwise diminish any providers’ sole authority and discretion with respect to all clinical decision-making for its patients.
Biological Dynamics, Inc., a company developing and commercializing its proprietary ExoVerita™ platform for early disease detection and other applications, today announced Peter C. Wulff as Chief Financial Officer effective January 1, 2023.
Read MoreBiological Dynamics today announced it has filed arbitration against two former employees, Richard Young and Bryan Rice, alleging that they have misappropriated Biological Dynamics’ proprietary technology to benefit their new company, EXOKĒRYX, Inc.
Read MoreBiological Dynamics, a company developing its exosome-isolation ExoVerita™ platform for early disease diagnostics, announced today that its Director of Medical Affairs, Harmeet Dhani, MD, MSc, will speak at the inaugural PRECEDE Early Detection Biomarker Summit in New York.
Read MoreBiological Dynamics, a company developing its exosome-isolation ExoVerita™ platform for early disease diagnostics, announced today it has received IRB approval and will soon begin to enroll patients in its ExoLuminate™ clinical study to validate its pancreatic ductal adenocarcinoma (PDAC) lab-developed test (LDT).
Read MoreBiological Dynamics, an exosome-isolation technology and early disease detection diagnostic company, today announced that it has partnered with both QURE Healthcare and Curta to explore how the company's assay for early detection of pancreatic ductal adenocarcinoma (PDAC) can improve patient outcomes, demonstrate the greatest value to clinicians, and enhance healthcare economics.
Read MoreBiological Dynamics is a private molecular diagnostics company located in San Diego. Our proprietary technology offers a novel, fast, and cost-effective lab-on-chip ACE platform that isolates nanoparticles from high conductance physiological solutions.
Our product, the TR(ACE)™ assay, will utilize the platform for monitoring treatment response in oncology. TR(ACE)™ has not been cleared or approved by the U.S. FDA or any foreign regulatory agency.
